Form 8-K - Current report:
SEC Accession No. 0000950170-23-024923
Filing Date
2023-05-30
Accepted
2023-05-30 16:53:14
Documents
14
Period of Report
2023-05-24
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K labp-20230524.htm   iXBRL 8-K 68090
2 EX-3.1 labp-ex3_1.htm EX-3.1 80885
3 EX-99.1 labp-ex99_1.htm EX-99.1 16712
  Complete submission text file 0000950170-23-024923.txt   301083

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT labp-20230524.xsd EX-101.SCH 2478
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT labp-20230524_lab.xml EX-101.LAB 13895
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT labp-20230524_pre.xml EX-101.PRE 10233
8 EXTRACTED XBRL INSTANCE DOCUMENT labp-20230524_htm.xml XML 4877
Mailing Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060
Business Address 1800 KRAFT DRIVE, SUITE 216 BLACKSBURG VA 24060 540-818-2844
Landos Biopharma, Inc. (Filer) CIK: 0001785345 (see all company filings)

EIN.: 815085535 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39971 | Film No.: 23977331
SIC: 2834 Pharmaceutical Preparations